- Home
- ABOS
as 02-21-2025 4:00pm EST
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CHARLOTTESVILLE |
| Market Cap: | 83.5M | IPO Year: | 2021 |
| Target Price: | $9.33 | AVG Volume (30 days): | 232.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.28 - $5.09 | Next Earning Date: | 03-25-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Acumen Pharmaceuticals Inc. (ABOS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 21 '25 | Sell | $1.59 | 3,418 | $5,434.62 | 161,127 | |
| Zuga Matt | ABOS | CFO & Chief Business Officer | Jan 21 '25 | Sell | $1.66 | 33,266 | $56,619.73 | 231,744 | |
| OConnell Daniel Joseph | ABOS | Chief Executive Officer | Jan 21 '25 | Sell | $1.59 | 12,619 | $20,102.07 | 667,488 | |
| Siemers Eric | ABOS | Chief Medical Officer | Jan 21 '25 | Sell | $1.59 | 3,219 | $5,118.21 | 170,298 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 3 '25 | Sell | $1.84 | 11,122 | $20,505.63 | 161,127 | |
| Barton Russell | ABOS | Chief Operating Officer | Jan 3 '25 | Sell | $1.86 | 7,636 | $14,225.10 | 89,231 | |
| Zuga Matt | ABOS | CFO & Chief Business Officer | Jan 3 '25 | Sell | $1.84 | 13,235 | $24,366.96 | 231,744 | |
| OConnell Daniel Joseph | ABOS | Chief Executive Officer | Jan 3 '25 | Sell | $1.84 | 47,778 | $87,873.30 | 667,488 | |
| Siemers Eric | ABOS | Chief Medical Officer | Jan 3 '25 | Sell | $1.85 | 10,859 | $20,046.80 | 170,298 |
Latest Acumen Pharmaceuticals Inc. News
ABOS Breaking Stock News: Dive into ABOS Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Promising US Penny Stocks To Consider In January 2025
TipRanks
a month ago
Acumen announces Phase 1 INTERCEPT-AD study publication
GlobeNewswire
a month ago
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
Simply Wall St.
3 months ago
I-Mab Leads Our Spotlight On 3 US Penny Stocks
GlobeNewswire
3 months ago
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
GuruFocus.com
3 months ago
Acumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
Thomson Reuters StreetEvents
3 months ago
Q3 2024 Acumen Pharmaceuticals Inc Earnings Call
GlobeNewswire
3 months ago
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
Compare ABOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABOS Acumen Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.